We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in our Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Journal Scan / Research · May 11, 2022

Safety and Efficacy of the Combination of 177Lu-PSMA-617 and Idronoxil in Men With End-Stage Metastatic Castration-Resistant Prostate Cancer

Journal of Nuclear Medicine


Additional Info

Journal of Nuclear Medicine
177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial
J. Nucl. Med. 2022 Apr 01;63(4)560-566, S Pathmanandavel, M Crumbaker, AO Yam, A Nguyen, C Rofe, E Hovey, C Gedye, EM Kwan, C Hauser, AA Azad, P Eu, AJ Martin, AM Joshua, L Emmett

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading